Cytosorbents (CTSO) Stock Price, News & Analysis

Company Overview

CytoSorbents Corporation is a medical device company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent technology to reduce circulating cytokines, inflammatory mediators, toxins and other substances associated with serious illness.

The company’s principal product, CytoSorb, is an extracorporeal blood purification device used in critical care and other clinical settings. It is designed to help manage excessive inflammation and is used with existing blood-pumping systems. CytoSorbents has also developed additional products and investigational therapies for applications including cardiac surgery, kidney disease, liver failure and other conditions in which blood purification may be beneficial.

Founded in 2001 and headquartered in Princeton, New Jersey, CytoSorbents serves healthcare markets internationally through direct sales and distribution partners. Its products have received regulatory clearances or approvals in various jurisdictions, including Europe, while other products and applications remain under clinical or regulatory review in certain markets.

Key Stats

• Today's Range: $3.59 to $3.80
• 50-Day Range: $3.73 to $8.00
• 52-Week Range: $3.59 to $19.71
• Volume: 6,229 shs
• Average Volume: 11,017 shs
• Market Capitalization: $11.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $107.50
• Consensus Rating: Hold

Cytosorbents Stock Analysis - MarketRank™

Cytosorbents scored higher than 41% of companies evaluated by MarketBeat, and ranked 287th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cytosorbents has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Cytosorbents has a consensus price target of $107.50, representing about 2,736.4% upside from its current price of $3.79.

Amount of Analyst Coverage

Cytosorbents has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cytosorbents are expected to grow in the coming year, from ($4.40) to ($0.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytosorbents is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytosorbents is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cytosorbents has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.26% of the float of Cytosorbents has been sold short.

Short Interest Ratio / Days to Cover

Cytosorbents has a short interest ratio ("days to cover") of 11.98, which indicates bearish sentiment.

Change versus previous month

Short interest in Cytosorbents has recently increased by 2.72%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytosorbents does not currently pay a dividend.

Dividend Growth

Cytosorbents does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Cytosorbents this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Cytosorbents to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $92,644.00 in company stock, which represents 0.7760% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Cytosorbents insiders have bought more of their company's stock than they have sold. Specifically, they have bought $92,644.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

7.80% of the stock of Cytosorbents is held by insiders.

Percentage Held by Institutions

32.87% of the stock of Cytosorbents is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CTSO
• CIK: 1175151
• Web: www.cytosorbents.com
• Phone: (973) 329-8885
• Fax: 732-329-8650
• Employees: 129
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Cytosorbents: $107.50
• High Price Target: $200.00
• Low Price Target: $15.00
• Potential Upside/Downside: +2,736.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.20 million
• Net Margins: -48.94%
• Pretax Margin: -50.01%
• Return on Equity: -431.65%
• Return on Assets: -41.94%

Debt

• Debt-to-Equity Ratio: 4.70
• Current Ratio: 0.66
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $37.22 million
• Price / Sales: 0.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.88 per share
• Price / Book: 2.02

Miscellaneous

• Outstanding Shares: 3,151,000
• Free Float: 2,905,000
• Market Cap: $11.94 million
• Optionable: Optionable
• Beta: 1.37